European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 313-320 , October 2003

D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder

  • Bruce R. Lawford

      Affiliations

    • Greenslopes Private Hospital, Brisbane, Queensland, Australia
    • ,
  • Ross McD. Young,

      Affiliations

    • Discipline of Psychiatry, Southern Clinical Division, School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
    • ,
  • Ernest P. Noble

      Affiliations

    • Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90024-1759, USA
    • Corresponding Author InformationCorresponding author. Neuropsychiatric Institute, 760 Westwood Boulevard, Los Angeles, CA 90024-1759, USA. Tel.: +1-310-825-1891; fax: +1-310-206-7309.
    • ,
  • Burnett Kann

      Affiliations

    • Nambour General Hospital, Nambour, Queensland, Australia
    • ,
  • Leanne Arnold

      Affiliations

    • Royal Brisbane Hospital, Brisbane, Queensland, Australia
    • ,
  • John Rowell

      Affiliations

    • Royal Brisbane Hospital, Brisbane, Queensland, Australia
    • ,
  • Terry L. Ritchie

      Affiliations

    • Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90024-1759, USA

Received 21 August 2002 ,Revised 30 October 2002 ,Accepted 30 October 2002.

References 

  1. Ainsworth K, Smith SE, Zetterstrom TS, Pei Q, Franklin M, Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology. 1998;140:470–477
  2. Aropax® (Paroxetine) product information, 1999. SmithKline Beecham (Aust) Pty Ltd, Item number 92536.
  3. Ballinger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and anxiety. J. Clin. Psychiatry. 2000;61(Suppl. 5):60–66
  4. Bonin B, Vandel P, Sechter D, Bizourard P. Paroxetine and galactorrhea. Pharmacopsychiatry. 1997;30:133–134
  5. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J. Clin. Psychiatry. 1999;60:857–860
  6. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7:25–47
  7. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder; a randomized controlled trial. J. Am. Med. Assoc. 2000;12(283):1837–1844
  8. Brody AL, Saxena S, Fairbanks LA, Alborzian S, Demaree HA, Maidment KM, et al. Personality changes in adult subjects with major depressive disorder treated with paroxetine. J. Clin. Psychiatry. 2000;61:349–355
  9. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann. Pharmacother. 1997;31:1481–1489
  10. Clark RN, Ashby CR, Dewey SL, Ramachandran PV, Strecker RE. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse. 1996;23:125–131
  11. Deahl MP, Gillham AB, Thomas J, Searle MM, Srinivasin M. Psychological sequelae following the Gulf War. Factors associated with subsequent morbidity and the effectiveness of psychological debriefing. Br. J. Psychiatry. 1994;165:60–65
  12. Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J. Neural. Transm. 1998;105:247–251
  13. Dziedzicka-Wasylewska M, Rogoz R, Klimek V, Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J. Neural. Transm. 1997;10:515–524
  14. Friedman MJ, Schnurr PP, McDonagh-Coyle A. Post-traumatic stress disorder in the military veteran. Psychiatr. Clin. North Am. 1994;17:265–277
  15. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, et al. Serotonin (2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 2000;36:205–221
  16. Grandy DK, Zhang Y, Civelli O. PCR detection of the Taq A RFLP at the DRD2 locus. Hum. Mol. Genet. 1993;2:2197
  17. Goodnick PJ, Chaudry T, Artadi J, Arcey S. Women’s issues in mood disorders. Expert Opin. Pharmacother. 2000;1:903–916
  18. Hall MJ. Breast tenderness and enlargement induced by sertraline. Am. J. Psychiatry. 1994;151:1395–1396
  19. Hidalgo RB, Davidson JRT. Selective serotonin reuptake inhibitors in post-traumatic stress disorder. J. Psychopharmacol. 2000;14:70–76
  20. Hitzemann RJ. The regulation of D2 dopamine receptor expression. Mol. Psychiatry. 1998;3:198–203
  21. Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK, et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav. Brain Res. 1999;105:105–116
  22. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry. 1999;4:290–296
  23. Kameda K, Kusumi I, Suzuki K, Miura J, Sasaki Y, Koyama T. Effects of citalopram on dopamine D2 receptor expression in the rat brain striatum. J. Mol. Neurosci. 2000;14:77–86
  24. Keane TM, Caddell JM, Taylor KL. Mississippi Scale for combat-related posttraumatic stress disorder: three studies in reliability and validity. J. Consult. Clin. Psychol. 1988;56:85–90
  25. Kestler LP, Malhorta AK, Finch , Adler C, Brier A. The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revised. Neuropsychiatry Neuropsychol. Behav. Neurol. 2000;1:48–52
  26. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. Neuroimaging. 1999;90:91–101
  27. Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not affected by TaqI polymorphism at the D2 receptor gene. Mol. Psychiatry. 1998;3:261–265
  28. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz P, et al. An open trial of paroxetine in patients with noncombat-related chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 1998;18:10–18
  29. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry. 2001;158:1982–1988
  30. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, et al. The effect of paroxetine on 5-HT (2A) receptors in depression: an [(18)F] setoperone PET imaging study. Am. J. Psychiatry. 2001;58:78–85
  31. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol. Psychiatry. 1999;46:1301–1308
  32. Ng N-K, Lee H-S, Wong PTH. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J. Neurosci. Res. 1999;55:600–607
  33. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor binding characteristics in alcoholism. Arch. Gen. Psychiatry. 1991;48:648–654
  34. Ormel J, Koeter MW, van der Brink W, Giel R. Concurrent validity of GHQ-28 and PSE as measures of change. Psychol. Med. 1989;19:1007–1013
  35. O’Toole BI, Marshall RP, Schureck RJ, Dobson M. Posttraumatic stress disorder and comorbidity in Australian Vietnam veterans: risk factors, chronicity and combat. Aust. N. Z. J. Psychiatry. 1998;32:32–42
  36. Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvalahti EKG, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry. 1998;3:256–260
  37. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT (1A) receptor activation contributes to ziprasidone induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry. 2000;48:229–237
  38. Schneier FR, Leibowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laurelle M. Low dopamine D2 receptor binding potential in social phobia. Am. J. Psychiatry. 2000;157:457–459
  39. Shively CA, Grant KA, Ehrenkaufer RL, Mach RH, Nader MA. Social stress, depression, and brain dopamine in female cynomolgus monkeys. Ann. NY Acad. Sci. 1997;807:574–577
  40. Silvestri S, Seeman MV, Negrete J-C, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology. 2000;152:174–180
  41. Stahl SM. Molecular neurobiology for practicing psychiatrists, part 4: transferring the message of chemical neurotransmission from presynaptic neurotransmitter to postsynaptic gene expression. J. Clin. Psychiatry. 1999;60:813–814
  42. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. D2 dopamine receptor gene (DRD2) TaqI A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7:479–484
  43. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry. 2001;62:860–868
  44. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62:655–703
  45. Ward W. Psychiatric morbidity in Australian veterans of the United Nations peacekeeping force in Somalia. Aust. N. Z. J. Psychiatry. 1997;31:184–193
  46. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the OHDA lesioned rat striatum. Neuroreport. 2001;12:1123–1126
  47. Yasuno F, Suhara T, Sudo Y, Yamamoto M, Inoue M, Okubo Y, et al. Relation among dopamine D(2) receptor binding, obesity and personality in normal human subjects. Neurosci. Lett,. 2001;300:59–61
  48. Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, et al. Posttraumatic stress disorder and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am. J. Psychiatry. 1997;154:1690–1695
  49. Zygmont M, Prigerson HG, Houck PR, Miller MD, Schear MK, Jacobs S, et al. A post-hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J. Clin. Psychiatry. 1998;59:241–245

PII: S0924-977X(02)00152-9

doi: 10.1016/S0924-977X(02)00152-9

European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 313-320 , October 2003

Article Tools

* Image Usage & Resolution